I think it warrants making a new publication here, $BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by $LLY's drug 'Donanemab'. I was long $LLY and have been trading in and out of $BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my $LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors $BIIB, so I'm only long Biogen currently.
Best of luck!
Cheers,
Ivan.
Best of luck!
Cheers,
Ivan.
Comment:
Trade closed: stop reached